Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development

Critical Reviews in Microbiology

Volumn 42, Issue 6, 2016, Pages 928-941

  Edwards, Jennifer L ^a   Jennings, Michael P ^b   Apicella, Michael A ^c   Seib, Kate L ^b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Candidate vaccine antigens; gonorrhea; infection models; multi drug resistance; Neisseria gonorrhoeae

Indexed keywords

BACTERIAL VACCINE; GONOCOCCAL VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); GONORRHEA; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; NEISSERIA GONORRHOEAE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VACCINATION; ANIMAL; GENETICS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; VIRULENCE;

ANIMALS; BACTERIAL VACCINES; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE; VIRULENCE;

EID: 84958536031     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2015.1105782     Document Type: Review

References (176)

1. P.Adamiak, A.J.Beddek, R.Pajon, A.B.Schryvers. (2012). Patterns of sequence variation within the Neisseria meningitidis lactoferrin binding proteins. Biochem Cell Biol 90:339–50
2. J.E.Aledort, E.W.HookIII, M.C.Weinstein, S.J.Goldie. (2005). The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis 32:425–36
3. M.A.Apicella, J.L.Edwards. (2007). Vaccine and compositions for the prevention and treatment of neisserial infections (Patent US7261901). United States
4. M.A.Apicella, M.Ketterer, F.K.Lee,. (1996). The pathogenesis of gonococcal urethritis in men:confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis 173:636–46
5. R.J.Arko. (1972). Neisseria gonorrhoeae:experimental infection of laboratory animals. Science 177:1200–1
6. R.J.Arko. (1989). Animal models for pathogenic Neisseria species. Clin Microbiol Rev 2:S56–9
7. L.M.Ball, A.K.Criss. (2013). Constitutively Opa-expressing and Opa-deficient Neisseria gonorrhoeae strains differentially stimulate and survive exposure to human neutrophils. J Bacteriol 195:2982–90
8. P.M.Barry, J.D.Klausner. (2009). The use of cephalosporins for gonorrhea:the impending problem of resistance. Expert Opin Pharmacother 10:555–77
9. S.N.Bhatia, D.E.Ingber. (2014). Microfluidic organs-on-chips. Nat Biotechnol 32:760–72
10. G.D.Biswas, J.E.Anderson, C.J.Chen,. (1999). Identification and functional characterization of the Neisseria gonorrhoeae lbpB gene product. Infect Immun 67:455–9
11. R.Bjerknes, H.K.Guttormsen, C.O.Solberg, L.M.Wetzler. (1995). Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst. Infect Immun 63:160–7
12. G.A.Bolan, P.F.Sparling, J.N.Wasserheit. (2012). The emerging threat of untreatable gonococcal infection. N Engl J Med 366:485–7
13. J.W.Boslego, E.C.Tramont, R.C.Chung,. (1991). Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9:154–62
14. N.A.Buss, S.J.Henderson, M.McFarlane,. (2012). Monoclonal antibody therapeutics:history and future. Curr Opin Pharmacol 12:615–22
15. M.J.Callaghan, S.Lewis, M.Sadarangani,. (2011). Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci. Infect Immun 79:2810–18
16. CDC. (2013). Antibiotic resistance threats in the United States, 2013. [On-line]. Available from:http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf [last accessed 7 Mar 2014]
17. CDC. (2012). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010:oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590–4
18. CDC. (2014). Sexually transmitted diseases surveillance 2013. [On-line]. Available from:http://www.cdc.gov/std/stats13/default.htm [last accessed 7 Mar 2014]
19. A.Chen, I.C.Boulton, J.Pongoski,. (2003). Induction of HIV-1 long terminal repeat-mediated transcription by Neisseria gonorrhoeae. AIDS 17:625–8
20. J.Choi, E.K.Lee, J.Choo,. (2015). Micro 3D cell culture systems for cellular behavior studies:culture matrices, devices, substrates, and in-situ sensing methods. Biotechnol J. [Epub ahead of print]. doi:10.1002/biot.201500092
21. V.L.Clark, J.S.Knapp, S.Thompson, K.W.Klimpel. (1988). Presence of antibodies to the major anaerobically induced gonococcal outer membrane protein in sera from patients with gonococcal infections. Microb Pathog 5:381–90
22. M.S.Cohen, J.G.Cannon, A.E.Jerse,. (1994). Human experimentation with Neisseria gonorrhoeae:rationale, methods, and implications for the biology of infection and vaccine development. J Infect Dis 169:532–7
23. M.S.Cohen, J.G.Cannon. (1999). Human experimentation with Neisseria gonorrhoeae:progress and goals. J Infect Dis 179:S375–9
24. M.S.Cohen, I.F.Hoffman, R.A.Royce,. (1997). Reduction of concentration of HIV-1 in semen after treatment of urethritis:implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 349:1868–73
25. J.G.Cole, A.E.Jerse. (2009). Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops. PLoS One 4:e8108
26. C.N.Cornelissen, A.Hollander. (2011). TonB-dependent transporters expressed by Neisseria gonorrhoeae. Front Microbiol 2:117
27. A.P.Craig, R.T.Gray, J.L.Edwards,. (2015). The potential impact of vaccination on the prevalence of gonorrhea. Vaccine 33:4520–5
28. A.K.Criss, H.S.Seifert. (2012). A bacterial siren song:intimate interactions between Neisseria and neutrophils. Nat Rev Microbiol 10:178–90
29. M.I.de Jonge, H.J.Hamstra, W.Jiskoot,. (2004). Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 22:4021–8
30. C.Dehio, S.D.Gray-Owen, T.F.Meyer. (2000). Host cell invasion by pathogenic Neisseriae. Subcell Biochem 33:61–96
31. J.L.Edwards, M.A.Apicella. (2002). The role of lipooligosaccharide in Neisseria gonorrhoeae pathogenesis of cervical epithelia:lipid A serves as a C3 acceptor molecule. Cell Microbiol 4:585–98
32. J.L.Edwards, M.A.Apicella. (2004). The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev 17:965–81
33. J.L.Edwards, M.A.Apicella. (2006). Neisseria gonorrhoeae PLD directly interacts with Akt kinase upon infection of primary, human, cervical epithelial cells. Cell Microbiol 8:1253–71
34. J.L.Edwards, E.J.Brown, K.A.Ault, M.A.Apicella. (2001). The role of complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical epithelia. Cell Microbiol 3:611–22
35. J.L.Edwards, E.J.Brown, S.Uk-Nham,. (2002). A co-operative interaction between Neisseria gonorrhoeae and complement receptor 3 mediates infection of primary cervical epithelial cells. Cell Microbiol 4:571–84
36. J.L.Edwards, D.D.Entz, M.A.Apicella. (2003). Gonococcal phospholipase D modulates the expression and function of complement receptor 3 in primary cervical epithelial cells. Infect Immun 71:6381–91
37. J.L.Edwards, J.Q.Shao, K.A.Ault, M.A.Apicella. (2000). Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells. Infect Immun 68:5354–63
38. J.N.Edwards, H.B.Morris. (1985). Langerhans' cells and lymphocyte subsets in the female genital tract. Br J Obstet Gynaecol 92:974–82
39. J.W.H.Eyre, B.H.Stewart. (1909). The treatment of gonococcus infections by vaccines. Lancet 174:76–81
40. M.L.Falsetta, T.B.Bair, S.C.Ku,. (2009). Transcriptional profiling identifies the metabolic phenotype of gonococcal biofilms. Infect Immun 77:3522–32
41. K.M.Farizo, D.L.Burns, T.M.Finn,. (2014). Clinical evaluation of pertussis vaccines:US Food and Drug Administration regulatory considerations. J Infect Dis 209:S28–31
42. T.A.Farley, D.A.Cohen, W.Elkins. (2003). Asymptomatic sexually transmitted diseases:the case for screening. Prev Med 36:502–9
43. B.Feinen, A.E.Jerse, S.L.Gaffen, M.W.Russell. (2010). Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol 3:312–21
44. R.N.Fichorova, P.J.Desai, F.C.GibsonIII, C.A.Genco. (2001). Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect Immun 69:5840–8
45. T.Fowler, M.Caley, R.Johal,. (2010). Previous history of gonococcal infection as a risk factor in patients presenting with gonorrhoea. Int J STD AIDS 21:277–8
46. K.K.Fox, J.C.Thomas, D.H.Weiner,. (1999). Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Am J Epidemiol 149:353–8
47. M.C.Gagliardi, S.Starnino, R.Teloni,. (2011). Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection. FEMS Immunol Med Microbiol 61:129–32
48. M.F.Gallo, M.Macaluso, L.Warner,. (2012). Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic:a longitudinal analysis of possible causal links. Ann Epidemiol 22:213–20
49. Garvin LE, Begum AAB, Bash MC, Jerse AE. (2010). Elicit broadly cross reactive, bactericidal antibodies against Neisseria gonorrhoeae. (Abstract P235), abstr International Pathogenic Neisseria Conference, Banff, Canada. [On-line]. Available from:http://neisseria.org/ipnc/history.shtml [last accessed 7 Mar 2014]
50. L.Greenberg, B.B.Diena, F.A.Ashton,. (1974). Gonococcal vaccine studies in Inuvik. Can J Public Health 65:29–33
51. S.Gulati, S.Agarwal, S.Vasudhev,. (2012). Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J Immunol 188:3416–25
52. S.Gulati, D.P.McQuillen, R.E.Mandrell,. (1996). Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids. J Infect Dis 174:1223–37
53. S.Gulati, B.Zheng, G.W.Reed,. (2013). Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog 9:e1003559
54. D.G.Hackam, D.A.Redelmeier. (2006). Translation of research evidence from animals to humans. JAMA 296:1731–2
55. F.Haghi, S.N.Peerayeh, S.D.Siadat, H.Zeighami. (2012). Recombinant outer membrane secretin PilQ(406-770) as a vaccine candidate for serogroup B Neisseria meningitidis. Vaccine 30:1710–14
56. K.A.Haines, J.Reibman, X.Y.Tang,. (1991). Effects of protein I of Neisseria gonorrhoeae on neutrophil activation:generation of diacylglycerol from phosphatidylcholine via a specific phospholipase C is associated with exocytosis. J Cell Biol 114:433–42
57. K.A.Haines, L.Yeh, M.S.Blake,. (1988). Protein I, a translocatable ion channel from Neisseria gonorrhoeae, selectively inhibits exocytosis from human neutrophils without inhibiting O2-generation. J Biol Chem 263:945–51
58. H.H.Handsfield, T.O.Lipman, J.P.Harnisch,. (1974). Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. N Engl J Med 290:117–23
59. H.A.Harvey, M.R.Ketterer, A.Preston,. (1997). Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae. Infect Immun 65:2420–7
60. H.A.Harvey, D.M.Post, M.A.Apicella. (2002). Immortalization of human urethral epithelial cells:a model for the study of the pathogenesis of and the inflammatory cytokine response to Neisseria gonorrhoeae infection. Infect Immun 70:5808–15
61. S.R.Hedges, M.S.Mayo, J.Mestecky,. (1999). Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun 67:3937–46
62. S.R.Hedges, D.A.Sibley, M.S.Mayo,. (1998). Cytokine and antibody responses in women infected with Neisseria gonorrhoeae:effects of concomitant infections. J Infect Dis 178:742–51
63. M.M.Hobbs, J.E.Anderson, J.T.Balthazar,. (2013). Lipid A's structure mediates Neisseria gonorrhoeae fitness during experimental infection of mice and men. MBio 4:e892–13
64. M.M.Hobbs, P.F.Sparling, M.S.Cohen,. (2011). Experimental gonococcal infection in male volunteers:cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2:123. doi:10.3389/fmicb.2011.00123
65. J.Holst, P.Oster, R.Arnold,. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV):lessons from past programs and implications for the future. Hum Vaccin Immunother 9:1241–53
66. E.W.Hook, H.H.Hansfield. (2008). Gonoccoal Infection in the Adult. In:K.K.Holmes, ed. Sexually transmitted diseases. New York:McGraw-Hill, 627–45
67. J.S.Huppert, E.Goodman, J.Khoury, G.Slap. (2005). Sexually transmitted infection testing and screening in hospital-based primary care visits by women. Obstet Gynecol 105:390–6
68. G.A.Jarvis. (1994). Analysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun 62:1755–60
69. A.E.Jerse, M.C.Bash, M.W.Russell. (2014). Vaccines against gonorrhea:current status and future challenges. Vaccine 32:1579–87
70. A.E.Jerse, M.S.Cohen, P.M.Drown,. (1994). Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med 179:911–20
71. A.E.Jerse, C.D.Deal. (2013). Vaccine research for gonococcal infections:where are we? Sex Transm Infect 89:iv63–8
72. A.E.Jerse, H.Wu, M.Packiam,. (2011). Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections. Front Microbiol 2:107
73. A.E.Jerse. (1999). Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun 67:5699–708
74. L.F.Johnson, L.Alkema, R.E.Dorrington. (2010). A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 86:169–74
75. R.A.Juneau, J.S.Stevens, M.A.Apicella, A.K.Criss. (2015). A thermonuclease of Neisseria gonorrhoeae enhances bacterial escape from killing by neutrophil extracellular traps. J Infect Dis 212:316–24
76. D.H.Kearns, R.J.O'Reilly, L.Lee, B.G.Welch. (1973). Secretory IgA antibodies in the urethral exudate of men with uncomplicated urethritis due to Neisseria gonorrhoeae. J Infect Dis 127:99–101
77. M.Kilian, J.Reinholdt. (1987). A hypothetical model for the development of invasive infection due to IgA1 protease-producing bacteria. Adv Exp Med Biol 216B:1261–9
78. R.D.Kirkcaldy, H.S.Weinstock, P.C.Moore,. (2014). The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 59:1083–91
79. A.Knight. (2007). Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern Lab Anim 35:641–59
80. A.Krawczyk, M.A.Arndt, L.Grosse-Hovest,. (2013). Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci USA 110:6760–5
81. M.M.Lahra, N.Ryder, D.M.Whiley. (2014). A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med 371:1850–1
82. B.C.Lee, A.B.Schryvers. (1988). Specificity of the lactoferrin and transferrin receptors in Neisseria gonorrhoeae. Mol Microbiol 2:827–9
83. W.C.Levine, V.Pope, A.Bhoomkar,. (1998). Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 177:167–74
84. L.A.Lewis, E.Burrowes, P.A.Rice, S.Ram. (2010). Interactions of Neisseria with complement. In:C.A.Genco, L.Wetzler, eds. Neisseria:molecular mechanisms of pathogenesis. Norfolk:Caister Academic Press, 123–44
85. D.A.Lewis, C.Sriruttan, E.E.Muller,. (2013). Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 68:1267–70
86. G.Li, H.Jiao, G.Jiang,. (2011). Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice. Clin Vaccine Immunol 18:1817–22
87. Y.Liu, N.K.Egilmez, M.W.Russell. (2013). Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12. J Infect Dis 208:1821–9
88. Y.Liu, W.Liu, M.W.Russell. (2014). Suppression of host adaptive immune responses by Neisseria gonorrhoeae:role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol 7:165–76
89. Y.Liu, M.W.Russell. (2011). Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1/Th2 by treatment with anti-transforming growth factor beta antibody generates immunological memory and protective immunity. MBio 2:e95–11
90. D.R.Lorenzen, D.Gunther, J.Pandit,. (2000). Neisseria gonorrhoeae porin modifies the oxidative burst of human professional phagocytes. Infect Immun 68:6215–22
91. R.E.Mandrell, M.A.Apicella. (1993). Lipo-oligosaccharides (LOS) of mucosal pathogens:molecular mimicry and host-modification of LOS. Immunobiology 187:382–402
92. D.Martin, N.Cadieux, J.Hamel, B.R.Brodeur. (1997). Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185:1173–83
93. I.Martin, P.Sawatzky, V.Allen,. (2012). Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada:2001–2010. Sex Transm Dis 39:316–23
94. J.R.Mascola, G.Stiegler, T.C.VanCott,. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–10
95. P.Massari, S.Ram, H.Macleod, L.M.Wetzler. (2003). The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 11:87–93
96. Z.A.McGee, A.P.Johnson, D.Taylor-Robinson. (1981). Pathogenic mechanisms of Neisseria gonorrhoeae:observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 143:413–22
97. L.A.McNamara, A.M.Shumate, P.Johnsen,. (2015). First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 135:798–804
98. D.P.McQuillen, S.Gulati, S.Ram,. (1999). Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J Infect Dis 179:124–35
99. J.Mestas, C.C.Hughes. (2004). Of mice and not men:differences between mouse and human immunology. J Immunol 172:2731–8
100. P.A.Mickelsen, E.Blackman, P.F.Sparling. (1982). Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from lactoferrin. Infect Immun 35:915–20
101. T.A.Mietzner, C.E.Thomas, M.M.Hobbs, M.S.Cohen. (2004). Vaccines against gonoccoal infection. In:M.M.Levine, J.B.Kaper, R.Rappouli, eds. New generation vaccines, 3rd ed. Revised and Expanded. New York:Marcel Dekker Inc., 755–73
102. P.Morales, P.Reyes, M.Vargas,. (2006). Infection of human fallopian tube epithelial cells with Neisseria gonorrhoeae protects cells from tumor necrosis factor alpha-induced apoptosis. Infect Immun 74:3643–50
103. I.M.Mosleh, L.A.Huber, P.Steinlein,. (1998). Neisseria gonorrhoeae porin modulates phagosome maturation. J Biol Chem 273:35332–8
104. R.K.Naz. (2012). Female genital tract immunity:distinct immunological challenges for vaccine development. J Reprod Immunol 93:1–8
105. J.Ngampasutadol, S.Ram, A.M.Blom,. (2005). Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci USA 102:17142–7
106. J.Ngampasutadol, S.Ram, S.Gulati,. (2008a). Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol 180:3426–35
107. J.Ngampasutadol, P.A.Rice, M.T.Walsh, S.Gulati. (2006). Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine 24:157–70
108. J.Ngampasutadol, C.Tran, S.Gulati,. (2008b). Species-specificity of Neisseria gonorrhoeae infection:do human complement regulators contribute? Vaccine 26:I62–6
109. NNDSS. (2015). National notifiable diseases surveillance system. Australian Government Department of Health. [On-line]. Available from:http://www9.health.gov.au/cda/source/rpt_3_sel.cfm [last accessed 1 Oct 2015]
110. W.B.Ober. (1970). Boswell's clap. JAMA 212:91–5
111. M.Ohnishi, D.Golparian, K.Shimuta,. (2011). Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538–45
112. R.J.O'Reilly, L.Lee, B.G.Welch. (1976). Secretory IgA antibody responses to Neisseria gonorrhoeae in the genital secretions of infected females. J Infect Dis 133:113–25
113. K.Owusu-EduseiJr, H.W.Chesson, T.L.Gift,. (2013). The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 40:197–201
114. M.Packiam, D.M.Shell, S.V.Liu,. (2006). Differential expression and transcriptional analysis of the alpha-2,3-sialyltransferase gene in pathogenic Neisseria spp. Infect Immun 74:2637–50
115. M.Packiam, S.J.Veit, D.J.Anderson,. (2010). Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses. Infect Immun 78:433–40
116. J.R.Papp, J.Schachter, C.A.Gaydos,. (2014). Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae-2014. MMWR Recomm Rep 63:1–19
117. M.B.Parr, E.L.Parr. (1991). Langerhans cells and T lymphocyte subsets in the murine vagina and cervix. Biol Reprod 44:491–8
118. A.Pettersson, J.Kortekaas, V.E.Weynants,. (2006). Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB. Vaccine 24:3545–57
119. R.K.Pettit, R.C.Judd. (1992). The interaction of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae with normal human serum. Mol Microbiol 6:729–34
120. P.Pound, S.Ebrahim, P.Sandercock,. (2004). Where is the evidence that animal research benefits humans? BMJ 328:514–17
121. G.A.Price, H.P.Masri, A.M.Hollander,. (2007). Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine 25:7247–60
122. J.Pudney, A.J.Quayle, D.J.Anderson. (2005). Immunological microenvironments in the human vagina and cervix:mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 73:1253–63
123. S.Ram, M.Cullinane, A.M.Blom,. (2001). Binding of C4b-binding protein to porin:a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 193:281–95
124. K.H.Ramsey, H.Schneider, A.S.Cross,. (1995). Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis 172:186–91
125. K.H.Ramsey, H.Schneider, R.A.Kuschner,. (1994). Inflammatory cytokine response to experimental human infection with Neisseria gonorrhoeae. Ann N Y Acad Sci 730:322–5
126. R.Rappuoli. (2007). Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25:1361–6
127. C.Rechner, C.Kuhlewein, A.Muller,. (2007). Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe 2:393–403
128. M.H.Rendi, A.Muehlenbachs, R.L.Garcia, K.L.Boyd. (2012). Female reproductive system. In:P.M.Treuting, S.M.Dintzis, eds. Comparative anatomy and histology:a mouse and human atlas. London, UK:Academic Press, 253–84
129. P.A.Rice, H.E.Vayo, M.R.Tam, M.S.Blake. (1986). Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 164:1735–48
130. C.D.Rinaudo, J.L.Telford, R.Rappuoli, K.L.Seib. (2009). Vaccinology in the genome era. J Clin Invest 119:2515–25
131. J.D.Ross, A.Moyes, H.Young. (1995). Serovar specific immunity to Neisseria gonorrhoeae:does it exist? Genitourin Med 71:367–9
132. J.B.Rothbard, R.Fernandez, L.Wang,. (1985). Antibodies to peptides corresponding to a conserved sequence of gonococcal pilins block bacterial adhesion. Proc Natl Acad Sci USA 82:915–19
133. E.Rotman, H.S.Seifert. (2014). The genetics of Neisseria species. Annu Rev Genet 48:405–31
134. M.Sadarangani, A.J.Pollard, S.D.Gray-Owen. (2011). Opa proteins and CEACAMs:pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 35:498–514
135. J.H.Saigh, C.C.Sanders, W.E.SandersJr. (1978). Inhibition of Neisseria gonorrhoeae by aerobic and facultatively anaerobic components of the endocervical flora:evidence for a protective effect against infection. Infect Immun 19:704–10
136. A.D.Santin, S.Bellone, J.J.Roman,. (2008). Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102:128–31
137. K.A.Schmidt, H.Schneider, J.A.Lindstrom,. (2001). Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers. Sex Transm Dis 28:555–64
138. H.Schneider, J.M.Griffiss, J.W.Boslego,. (1991). Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med 174:1601–5
139. G.K.Schoolnik, J.Y.Tai, E.C.Gotschlich. (1983). A pilus peptide vaccine for the prevention of gonorrhea. Prog Allergy 33:314–31
140. K.L.Seib, R.Rappuoli. (2010). Difficulties in developing neisserial vaccines. In:C.A.Genco, L.M.Wetzler, eds. Neisseria:molecular mechanisms of pathogenesis. Norwich:Horizon Scientific Press, 195–226
141. K.L.Seib, M.Scarselli, M.Comanducci,. (2015). Neisseria meningitidis factor H-binding protein fHbp:a key virulence factor and vaccine antigen. Expert Rev Vaccines 14:841–59
142. K.L.Seib, M.P.Simons, H.J.Wu,. (2005). Investigation of oxidative stress defenses of Neisseria gonorrhoeae by using a human polymorphonuclear leukocyte survival assay. Infect Immun 73:5269–72
143. H.S.Seifert, C.J.Wright, A.E.Jerse,. (1994). Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 93:2744–9
144. J.Seok, H.S.Warren, A.G.Cuenca,., Inflammation, Host Response to Injury LSCRP. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507–12
145. L.Serino, B.Nesta, R.Leuzzi,. (2007). Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization. Mol Microbiol 64:1391–403
146. D.M.Shell, L.Chiles, R.C.Judd,. (2002). The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein. Infect Immun 70:3744–51
147. L.K.Shewell, S.C.Ku, B.L.Schulz,. (2013). Recombinant truncated AniA of pathogenic Neisseria elicits a non-native immune response and functional blocking antibodies. Biochem Biophys Res Commun 431:215–20
148. M.Siegel, D.Olsen, C.Critchlow, T.M.Buchanan. (1982). Gonococcal pili:safety and immunogenicity in humans and antibody function in vitro. J Infect Dis 145:300–10
149. M.P.Simons, W.M.Nauseef, M.A.Apicella. (2005). Interactions of Neisseria gonorrhoeae with adherent polymorphonuclear leukocytes. Infect Immun 73:1971–7
150. M.P.Simons, W.M.Nauseef, T.S.Griffith, M.A.Apicella. (2006). Neisseria gonorrhoeae delays the onset of apoptosis in polymorphonuclear leukocytes. Cell Microbiol 8:1780–90
151. H.Smith, N.J.Parsons, J.A.Cole. (1995). Sialylation of neisserial lipopolysaccharide:a major influence on pathogenicity. Microb Pathog 19:365–77
152. D.S.Stephens. (1989). Gonococcal and meningococc pathogenesis as defined by human cell, cell culture, and organ culture assays. Clin Microbiol Rev 2:S104–11
153. E.A.Stohl, A.K.Criss, H.S.Seifert. (2005). The transcriptome response of Neisseria gonorrhoeae to hydrogen peroxide reveals genes with previously uncharacterized roles in oxidative damage protection. Mol Microbiol 58:520–32
154. 2- and neutrophil-mediated killing. MBio 4:e399–13
155. M.Stork, M.P.Bos, I.Jongerius,. (2010). An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog 6:e1000969
156. C.F.Su, H.J.Tsai, C.Kuo,. (2008). Primary non-Hodgkin's lymphoma of the uterus, cervix and parametrium treated by combined immunochemotherapy. J Obstet Gynaecol Res 34:749–53
157. J.Swanson, O.Barrera, J.Sola, J.Boslego. (1988). Expression of outer membrane protein II by gonococci in experimental gonorrhea. J Exp Med 168:2121–9
158. J.Swanson, K.Robbins, O.Barrera,. (1987). Gonococcal pilin variants in experimental gonorrhea. J Exp Med 165:1344–57
159. J.W.Tapsall, F.Ndowa, D.A.Lewis, M.Unemo. (2009). Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7:821–34
160. M.M.Timmerman, J.Q.Shao, M.A.Apicella. (2005). Ultrastructural analysis of the pathogenesis of Neisseria gonorrhoeae endometrial infection. Cell Microbiol 7:627–36
161. E.C.Tramont, J.C.Sadoff, J.W.Boslego,. (1981). Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. J Clin Invest 68:881–8
162. E.C.Tramont. (1977). Inhibition of adherence of Neisseria gonorrhoeae by human genital secretions. J Clin Invest 59:117–24
163. E.C.Tramont. (1989). Gonococcal vaccines. Clin Microbiol Rev 2:S74–7
164. Tramont EC, Ciak J, Boslego J, et al. (1980). Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeae. J Infect Dis 142:23–31
165. M.Unemo, D.Golparian, R.Nicholas,. (2012). High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France:novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56:1273–80
166. M.Unemo, D.Golparian, A.Stary, A.Eigentler. (2011). First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 16:19998–20000
167. M.Unemo, R.A.Nicholas. (2012). Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 7:1401–22
168. M.Unemo, W.M.Shafer. (2014). Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century:past, evolution, and future. Clin Microbiol Rev 27:587–13
169. M.Virji, J.E.Heckels. (1984). The role of common and type-specific pilus antigenic domains in adhesion and virulence of gonococci for human epithelial cells. J Gen Microbiol 130:1089–95
170. M.Virji, S.M.Watt, S.Barker,. (1996). The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 22:929–39
171. D.M.Warner, J.P.Folster, W.M.Shafer, A.E.Jerse. (2007). Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 196:1804–12
172. D.M.Warner, W.M.Shafer, A.E.Jerse. (2008). Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 70:462–78
173. B.G.Welch, R.J.O'Reilly. (1973). An indirect fluorescent-antibody technique for study of uncomplicated gonorrhea. I. Methodology. J Infect Dis 127:69–76
174. WHO. (2011). Prevalence and incidence of selected sexually transmitted infections. Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates. on World Health Organisation. [On-line]. Available from http://www.who.int/reproductivehealth/publications/rtis/9789241502450/en/ [last accessed 7 Mar 2014]
175. WHO. (2012). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae (2012), on World Health Organization (WHO), Department of Reproductive Health and Research. [On-line]. Available from:http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/ [last accessed 7 Mar 2014]
176. G.R.Yeaman, J.E.Collins, M.W.Fanger,. (2001). CD8+ T cells in human uterine endometrial lymphoid aggregates:evidence for accumulation of cells by trafficking. Immunology 102:434–40